GRANULES INDIA

BSE: 532482 30 Sep 2025

Healthcare

₹ 516

Granules India Ltd. specializes in Pharmaceuticals within the Healthcare sector.

GRANULES INDIA

BSE: 532482 30 Sep 2025

Healthcare

₹ 516

Granules India Ltd. specializes in Pharmaceuticals within the Healthcare sector.

Book Value

153.0

Dividend Yield

0.29%

Debt to Equity

0.39

Stock P/E

26.2

Market Cap

12,519 Cr

GRANULES INDIA - Share Price & Details

Market Cap

₹12,519

High /Low

628.0 / 412.0

Stock P/E

26.2

Book Value

₹153.0

Dividend Yield

0.29

ROCE

15.1

ROE

₹13.9

Face Value

1.0

PEG Ratio

5.31

EVEBITDA

₹13.9

Debt

1,455

CMP / FCF

54.8

Debt to equity

₹0.39

NP Ann

502

High price all time

725.0

Piotroski score

₹7.0

Graham Number

261.0

No. Eq. Shares

24.3

Net CF

₹85.0

Net profit

480

Price to book value

3.37

Interest Coverage

₹7.18

Low price all time

2.53

Industry PE

33.0

Reserves

₹3,691

Free Cash Flow

₹297

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
22 Aug 2025	Deven Choksey	Buy	₹461.7	₹533	16.2%	moneycontrol	View
05 Jun 2025	Deven Choksey	Buy	₹533.9	₹612	15.4%	moneycontrol	View
28 May 2025	Motilal Oswal	Buy	₹522.05	₹600	15%	moneycontrol	View
17 Feb 2025	Geojit Financial Services	Buy	₹512.55	₹580	11%	moneycontrol	View
27 Jan 2025	KRChoksey	Buy	₹582.35	₹700	28.5%	moneycontrol	View
25 Jan 2025	Motilal Oswal	Buy	₹582.35	₹665	28.7%	moneycontrol	View
08 Nov 2024	KRChoksey	Buy	₹582.9	₹700	12.4%	moneycontrol	View
06 Nov 2024	Sharekhan	Buy	₹576.3	₹700	12.4%	moneycontrol	View
12 Sep 2024	Motilal Oswal	Buy	₹564.8	₹680	9%	moneycontrol	View
19 Aug 2024	KRChoksey	Buy	₹662.2	₹769	23.2%	moneycontrol	View
31 Jul 2024	Motilal Oswal	Buy	₹630.35	₹680	27.3%	moneycontrol	View
26 Jun 2024	Sharekhan	Buy	₹503.05	₹600	12.3%	moneycontrol	View
03 Jun 2024	Sharekhan	Buy	₹440.95	₹515	-3.5%	moneycontrol	View
17 May 2024	KRChoksey	Buy	₹401.8	₹443	-17%	moneycontrol	View
23 Mar 2024	Sharekhan	Buy	₹431.15	₹500	-6.3%	moneycontrol	View
23 Jan 2024	Sharekhan	Buy	₹411.45	₹500	-6.3%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	NA	NA	NA	NA	0
GRANULES INDIA LTD.	8233.6	694.85	8102.08	2.86	12,519	26.2
ALIVUS LIFE SCIENCES LIMITED	6108.31	1215.35	6018.46	9.88	11522	23.2
Blue Jet Healthcare Limited	3630.12	911.7	3547.58	5.26	11204	31.2

Peer Comparison Chart

About GRANULES INDIA

Granules India Ltd., with Security Code 532482, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Granules India and NIPER S.A.S Nagar launch Centre of Excellence for Sustainable Pharma Innovation

(09 Sep 2025)

Granules India and NIPER S.A.S Nagar launch Centre of Excellence for Sustainable Pharma Innovation. Our Bureau, Mumbai

Granules India, NIPER SAS Nagar inaugurate Centre of Excellence for Sustainable Pharma Innovation

(08 Sep 2025)

Mumbai: Granules India Limited, in partnership with the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar,...

Granules India's (NSE:GRANULES) 19% CAGR outpaced the company's earnings growth over the same three-year period

(08 Sep 2025)

By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with...

Stock Radar: Why Granules India is showing signs of potential reversal; stock down by over 29% from highs

(08 Sep 2025)

Granules India Ltd. broke out from a descending triangle pattern, signaling a potential upward movement. Experts suggest short-term traders...

Granules India’s CSR Journey: From Short-Term Relief to Lasting Change

(06 Sep 2025)

Granules India has long been recognized for its global presence in pharmaceuticals, but what sets the company apart today is the way it has...

Granules India Shows Strong Short-Term Gains Amid Mixed Long-Term Performance Trends

(02 Sep 2025)

Granules India, a small-cap pharmaceutical company, experienced notable gains on August 29, 2025, outperforming its sector.

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	1,013.9	821.0	1,009.4	984.5	940.2	852.0	568.0	842.2	768.0	810.2
Expenses	796.6	664.2	801.0	737.6	750.9	674.5	465.4	674.3	651.0	666.6
Operating Profit	217.3	156.8	208.4	246.9	189.3	177.4	102.6	167.9	117.0	143.6
OPM %	21.43%	19.1%	20.65%	25.08%	20.13%	20.82%	18.06%	19.93%	15.23%	17.73%
Other Income	2.6	0.4	1.3	0.7	3.4	1.8	2.8	5.6	61.2	1.0
Interest	14.1	14.8	17.6	19.8	19.8	17.5	14.6	17.2	13.5	13.7
Depreciation	37.8	35.3	36.0	36.2	36.4	35.8	34.7	37.7	38.0	39.5
Profit before tax	168.0	107.2	156.0	191.6	136.5	125.9	56.1	118.6	96.0	103.6
Tax %	-25.4%	-25.5%	-25.5%	-25.5%	-28.8%	-25.5%	-26.2%	-24%	-25.7%	24%
Net Profit	125.3	79.8	116.2	142.7	97.2	93.8	41.4	90.1	94.1	69.5
EPS in Rs	5.17	3.29	4.8	5.88	4.01	3.87	1.71	3.72	0	2.86

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	1,146.1	1,195.5	985.5	1,189.5	1,155.6	1,175.8	1,179.9	966.6	1,137.7	1,197.4
Expenses	914.8	967.4	848.7	976.5	905.1	920.1	920.6	763.3	907.4	945.0
Operating Profit	231.3	228.1	136.8	213.0	250.5	255.7	259.3	203.3	230.3	252.4
OPM %	20.18%	19.08%	13.88%	17.9%	21.68%	21.75%	21.97%	21.03%	20.24%	21.08%
Other Income	0.9	3.4	0.3	1.5	0.7	1.9	2.1	3.3	5.7	32.7
Interest	17.0	18.8	22.5	26.0	28.6	28.8	27.0	25.7	26.6	24.0
Depreciation	48.4	48.7	49.2	52.5	52.4	53.2	52.9	52.5	56.6	63.5
Profit before tax	166.9	164.0	65.5	136.0	170.1	175.6	181.4	128.4	152.8	166.9
Tax %	-25.5%	-27.1%	-26.8%	-24.9%	-26.1%	-26.2%	-25.8%	-24.3%	-23%	-23%
Net Profit	124.3	119.6	47.9	102.1	125.7	129.6	134.6	97.2	117.6	152.0
EPS in Rs	5.1	4.93	1.98	4.22	5.18	5.35	5.55	4.01	4.85	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	14%
5 Years:	12%
3 Years:	6%
TTM:	-16%

Compounded Profit Growth
10 Years:	18%
5 Years:	22%
3 Years:	-8%
TTM:	-31%

Stock Price CAGR
10 Years:	20%
5 Years:	26%
3 Years:	23%
1 Year:	20%

Compounded Sales Growth
10 Years:	15%
5 Years:	15%
3 Years:	12%
TTM:	-1%

Compounded Profit Growth
10 Years:	18%
5 Years:	11%
3 Years:	-10%
TTM:	21%

Stock Price CAGR
10 Years:	20%
5 Years:	26%
3 Years:	23%
1 Year:	20%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

GRANULES INDIA

GRANULES INDIA

GRANULES INDIA - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About GRANULES INDIA

Order Book

Latest News

Granules India and NIPER S.A.S Nagar launch Centre of Excellence for Sustainable Pharma Innovation

Granules India, NIPER SAS Nagar inaugurate Centre of Excellence for Sustainable Pharma Innovation

Granules India's (NSE:GRANULES) 19% CAGR outpaced the company's earnings growth over the same three-year period

Stock Radar: Why Granules India is showing signs of potential reversal; stock down by over 29% from highs

Granules India’s CSR Journey: From Short-Term Relief to Lasting Change

Granules India Shows Strong Short-Term Gains Amid Mixed Long-Term Performance Trends

Advanced Enzyme Technologies Ltd leads gainers in 'A' group

Granules India Ltd soars 1.1%, up for third straight session

SENSEX, NIFTY rangebound; Reliance, Relaxo Footwear, Granules India among buzzing stocks

F&O Changes: Eight stocks that will only trade in the cash market from Friday

Can Granules India leverage its strong product pipeline to offset recent profit declines?

Granules arm gets USFDA observation for Shamirpet plant

Granules India Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr

Granules India Q1FY26 Revenue at ₹12,101 Mn, Up 3% YoY

Granules India Q1 Revenue Rises 3 per cent On North America Growth

Granules India Q1 Results: Revenue rises 3% on North America push; margin narrows

Paracetamol maker Granules India's quarterly profit drops on supply backlog

Granules India Q1 Results: Net profit dips 16%, revenue rises on strong sales growth in North America

Q1 Results Highlights: Hindalco, Nykaa, Zydus Lifesciences profit rise; Karnataka Bank, MRF, others report declines

Anakapalli collector inaugurates transformed hostel in Parawada under Granules India CSR Initiative

Granules India arm gets 1 USFDA observation for Hyderabad facility

Be Sure To Check Out Granules India Limited (NSE:GRANULES) Before It Goes Ex-Dividend

Granules India CEO K V Sitaram Rao resigns

Granules India Limited (532482) Hits 52 Week High - Explosive capital appreciation

Buy, Sell Or Hold: NACL Industries, Hathway Cable, Dodla Dairy, Granules India, Garware Hi-Tech

Granules India CEO Dr Kandiraju Venkata Sitaram Rao to step down

Granules India CFO Dr. Kandiraju Venkata Sitaram Rao resigns

Granules India (NSE:GRANULES) Has Announced A Dividend Of ₹1.50

Granules India Ltd receives 1 observation from USFDA for Chantilly facility

Granules India Shares Gain 2% on 1 Observation from USFDA

Granules India shares in focus after US FDA flags observation at Telangana API facility

Stocks to watch: HAL, MakeMyTrip, ONGC, Zen Tech, Bank of India, BEL shares in focus

Granules India's Bonthapally facility completes US FDA inspection with one observation

Granules Indias API Facility In Telangana Gets FDA Observation

Granules India Wraps Up USFDA Inspection at Bonthapally with Single Observation

Granules India Share Price Target at Rs 612: Deven Choksey Research

Granules India Share Price Today - Granules India Stock Price Live NSE/BSE

Q4 Results Today: MTNL Net Loss Narrows; IRCTC Profit Beats Estimates, Welspun Corp Profit More Than Doubles

Granules India posts Q4 FY25 PAT at Rs. 152 Cr

Granules India Plans To Resume Normal Operations At Gagillapur Facility By Q3

Granules India Limited (NSE:GRANULES) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Granules India Q4 Net Profit Rises 18% YoY to ₹152 Crore

Granules FY25 PAT up 24% despite Gagillapur plant productivity woes

Granules India Q4 Results: Net profit rises 17%, EBITDA slips; board recommends final dividend for FY25

Q4 Results highlights: Natco Pharma & Granules Q4 profit up, Finolex Q4 profit at ₹192 cr, JSW Holdings, 3M India and Bata India profit declines, IRCTC, SAIL, , Dr Agarwals Health Care, Natco Pharma, Welspun Corp to announce Q4 results, LIC, Techno Elec

Granules India Limited's (NSE:GRANULES) CEO Krishna Chigurupati is the most upbeat insider, and their holdings increased by 3.8% last week

Granules India Q4 Results: 50% fall in European sales offset by North America, India

Q4 Results Highlights: Bata India consolidated net profit declines 28%, board recommends dividend of ₹9 per share for FY25

Granules India bags EcoVadis’ Gold Rating

Benign Growth For Granules India Limited (NSE:GRANULES) Underpins Its Share Price

Granules India G N Prashanth resigns as Senior Vice President - Corporate Quality

Granules India Limited Announces Change in Registered Office Location

Granules Indias Board Approves Restructuring Plan Involving US Subsidiaries

Granules India completes aquisition of Swiss- based CDMO, Senn Chemicals

USFDA pulls up Granules India for lapses in maintaining storage facilities, equipment at Telangana plant

Granules India Fails To Follow US FDA Mandated Safety Procedures

Granules India gets US food regulator's warning for lapses at Telangana plant

Explained — Why Granules India shares fell on Wednesday

Granules India Ltd Falls 3.02%

USFDA issues warning letter for Granules India Gagillapur plant, new product approvals to take a hit

Granules India Gagilapur unit gets USFDA warning letter, new product approval to see impact

Granules India shares tumble almost 8% after USFDA issues warning letter for its Gagillapur facility

US FDA issues warning letter to Granules India's Gagillapur facility

Granules India share price falls nearly 8% as US FDA issues warning letter to Gagillapur facility

Granules India shares in focus on acquiring Swiss firm for Rs 192 cr

Accumulate Granules India; target of Rs 580: Geojit Financial Services

Gagillapur plant closure over USFDA observations pulls Granules Q3 PAT down 6%

Stock recommendations by analysts for January 8: ONGC, Granules India and Bank of Baroda